Document is current
Any future updates will be listed below
-
Authors
Higuchi, Akiko
Tamura, Kaoru https://orcid.org/0000-0002-7943-5458
Watanabe, Yuko https://orcid.org/0000-0002-5703-9382
Abe, Tatsuya
Nakada, Mitsutoshi
Tanaka, Shota
Okita, Yoshiko
Nagane, Motoo
Hirose, Yuichi
Fujimaki, Takamitsu
,
- License Information
-
More Information
Article History
Received: 21 May 2026
Accepted: 4 August 2026
First Online: 18 August 2026
Declarations
Conflict of interest: Dr. Nagane has received honoraria from Ono Pharmaceutical Co., Ltd. and Servier Japan; research funding from Ono Pharmaceutical Co., Ltd.; and scholarship donations from Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Daiichi Sankyo Co., Ltd., Bayer Yakuhin, Ltd., Medtronic Japan Co., Ltd., and HOYA Technosurgical Corporation. Dr. Hirose has served on the Advisory Board of Nihon Servier; has received honoraria from Novocure, Nihon Servier, and Daiichi Sankyo Co., Ltd.; and has received fees for promotional materials from Nihon Servier.
Ethical approval: The study protocol was approved by the Ethics and Academic Committees of the Japan Society for Neuro-Oncology (JSNO2021-1).
Informed consent: Informed consent was obtained electronically from all participants prior to participation in the survey.
